Latest News

ITN Director and founder, Jeffrey A. Bluestone has accepted the position of Executive Vice Chancellor and Provost at the University of California, San Francisco, pending approval by the UC Regents. Details of his new appointment may be found on the UCSF website .  As he embarks upon his latest challenge at UCSF, Bluestone will step down as Director of the Immune Tolerance Network.  From its inception a decade ago, Bluestone has led the ITN with extraordinary dedication.

The ITN's START research trial for new-onset type 1 diabetes has received the approval of its Data Safety and Monitoring Board to accept patients aged 12-18 years into the study. The decision was made after a review of safety data from the initial group of 10 adult subjects enrolled into the study. The trial is now open to individuals between the ages of 12-35 who have been diagnosed with new-onset type 1 diabetes within the past 3 months.  The START trial is being conducted under the direction of principal investigator Dr.

Results of the ITN's study of a novel vaccine for treatment of new onset type 1 diabetes has been published in the Journal of Autoimmunity. Led by Joslin Diabetes Clinic's Tihamer Orban, the study determined that a vaccine comprised of insulin B-chain in incomplete Freund's adjuvant was generally safe and well-tolerated.